Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Single-Arm, Phase 3b Study of the Incidence of Severe COVID-19 and Adverse Events Following AZD1222 COVID-19 Vaccination in Botswana Against SARS-CoV-2, AZD1222 - ESR-21-21311

NCT05715944 is registered in ClinicalTrials.gov with Botswana Harvard AIDS Institute Partnership as lead sponsor.

NCT NCT05715944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05715944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Single-Arm, Phase 3b Study of the Incidence of Severe COVID-19 and Adverse Events Following AZD1222 COVID-19 Vaccination in Botswana Against SARS-CoV-2, AZD1222 - ESR-21-21311
Lead sponsor
Botswana Harvard AIDS Institute Partnership
Phase
Phase 3
Overall status
Completed
Start date
September 15, 2021
Completion date
December 30, 2022
Enrollment
10,888 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19